Market Overview:
The global next generation cancer diagnostic devices market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of cancer, technological advancements in diagnostics, and rising demand for personalized medicine. Based on type, the next generation sequencing segment is expected to account for the largest share of the global market in 2018. This segment is projected to grow at a CAGR of 11.5% during the forecast period. Next generation sequencing offers several advantages over other technologies such as qPCR & multiplexing and Lab-on-a-chip (LOAC), which are expected to boost its adoption in cancer diagnosis over the forecast period. Based on application, biomarker development is estimated to be one of the fastest growing segments in 2018 and is projected grow at a CAGR of 12%.
Product Definition:
A next generation cancer diagnostic device is a medical device that uses cutting-edge technology to diagnose cancer. These devices are often more accurate and sensitive than traditional diagnostic methods, and they can help doctors to better understand the nature of a patient's cancer. Next generation cancer diagnostic devices are important because they can help doctors to provide more accurate treatment plans and improve the chances of cure for patients with cancer.
Next Generation Sequencing:
Next generation sequencing (NGS) is a powerful technology that has revolutionized the field of cancer research and diagnosis. It allows comprehensive genomic analysis in a relatively short period of time. The technology is used to sequence the human genome in order to understand, treat and prevent diseases. NGS can be used for basic as well as applied research applications such as genetic testing, biomarker discovery & validation, drug development & toxicity screening etc.
qPCR & Multiplexing:
The Next Generation Cancer Diagnostic (NGCD) devices market is expected to witness significant growth over the forecast period. The major factor that propels the growth of this market includes increasing prevalence of cancer and growing demand for early diagnostic methods. According to WHO, in 2012, worldwide cancer incidences were nearly 14 million and it is estimated that about 8.2 million deaths were reported due to this disease.
Application Insights:
CTC analysis segment dominated the market in 2017. This can be attributed to the rising prevalence of cancer and increasing demand for sensitive, rapid, non-invasive and accurate diagnostic methods. Moreover, growing R&D investments by several companies for the development of next generation CTC tools is expected to drive growth during the forecast period. For instance, in March 2018 Illumina collaborated with Merck KGaA & Pfizer Inc. for a multi-year research collaboration to develop innovative CTC technology through an exclusive license from UMIBiolabs GmbH & Co.KG¢â‚¬â„¢s ctDNA testing platform is anticipated to enhance precision of genomic testing and support future advancements in oncology diagnostics (Merck).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, continuous R&D activities for development of advanced diagnostic products, and high adoption rate for technologically advanced cancer diagnostics in this region. In addition, increasing government funding for cancer research is also expected to drive growth during the forecast period. For instance, according to statistics published by American Cancer Society (ACS), it was estimated that about 1 million new cases will be diagnosed in 2019 and more than 600 thousand people will die due to this disease each year as of 2018.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to increasing awareness regarding early diagnosis among population especially those living in Japan & China coupled with government initiatives such as “One Million Genomes Project†which aims at sequencing one million genomes by 2020 from Asian countries are some factors contributing toward regional growth during the forecast period.
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is primarily due to the aging population and the increase in lifestyle-related cancers. This is expected to drive the demand for Next Generation Cancer Diagnostic Devices market over the forecast period.
- Technological advancements: The technological advancements in Next Generation Cancer Diagnostic Devices market are helping to improve accuracy and efficiency of diagnosis, which is driving the market growth.
- Government initiatives: Governments across different countries are investing in cancer research and development, which is aiding the growth of Next Generation Cancer Diagnostic Devices market globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Next Generation Cancer Diagnostic Devices Market Research Report
By Type
Next Generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC), Protein Microarrays, DNA Microarrays, Reverse Transcriptase-PCR (RT-PCR)
By Application
Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis
By Companies
Roche Holding Ltd.(Switzerland), Abbott Laboratories(US), Siemens Healthcare(Germany), Agilent Technologies Inc(Germany), Illumina Inc.(US), Becton Dickinson and Co.(US), QIAGEN N.V.(Germany), Affymetrix Inc.(US), Johnson & Johnson(US), Thermo Fisher Scientific Inc.(US), GE Healthcare(England), Life Technologies Corp.(US), Luminex Corp.(US), Cepheid Inc.(US), Allegro Diagnostics Corp.(Brazil)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Next Generation Cancer Diagnostic Devices Market Report Segments:
The global Next Generation Cancer Diagnostic Devices market is segmented on the basis of:
Types
Next Generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC), Protein Microarrays, DNA Microarrays, Reverse Transcriptase-PCR (RT-PCR)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche Holding Ltd.(Switzerland)
- Abbott Laboratories(US)
- Siemens Healthcare(Germany)
- Agilent Technologies Inc(Germany)
- Illumina Inc.(US)
- Becton Dickinson and Co.(US)
- QIAGEN N.V.(Germany)
- Affymetrix Inc.(US)
- Johnson & Johnson(US)
- Thermo Fisher Scientific Inc.(US)
- GE Healthcare(England)
- Life Technologies Corp.(US)
- Luminex Corp.(US)
- Cepheid Inc.(US)
- Allegro Diagnostics Corp.(Brazil)
Highlights of The Next Generation Cancer Diagnostic Devices Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Next Generation Sequencing
- qPCR & Multiplexing
- Lab-on- a- chip (LOAC)
- Protein Microarrays
- DNA Microarrays
- Reverse Transcriptase-PCR (RT-PCR)
- By Application:
- Biomarker Development
- CTC Analysis
- Proteomic Analysis
- Epigenetic Analysis
- Genetic Analysis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Next Generation Cancer Diagnostic Devices Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Next Generation Cancer Diagnostic Devices (NGCDs) are a new class of cancer diagnostic devices that use imaging and other technologies to help doctors diagnose and treat cancer. NGCDs can be used to detect small tumors in the early stages, when they are most likely to be cured with treatment. They can also help identify cancers that have spread beyond where they were originally located, making them more likely to require more aggressive treatments.
Some of the key players operating in the next generation cancer diagnostic devices market are Roche Holding Ltd.(Switzerland), Abbott Laboratories(US), Siemens Healthcare(Germany), Agilent Technologies Inc(Germany), Illumina Inc.(US), Becton Dickinson and Co.(US), QIAGEN N.V.(Germany), Affymetrix Inc.(US), Johnson & Johnson(US), Thermo Fisher Scientific Inc.(US), GE Healthcare(England), Life Technologies Corp.(US), Luminex Corp.(US), Cepheid Inc.(US), Allegro Diagnostics Corp.(Brazil).
The next generation cancer diagnostic devices market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Next Generation Cancer Diagnostic Devices Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Next Generation Cancer Diagnostic Devices Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Next Generation Cancer Diagnostic Devices Market - Supply Chain
4.5. Global Next Generation Cancer Diagnostic Devices Market Forecast
4.5.1. Next Generation Cancer Diagnostic Devices Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Next Generation Cancer Diagnostic Devices Market Size (000 Units) and Y-o-Y Growth
4.5.3. Next Generation Cancer Diagnostic Devices Market Absolute $ Opportunity
5. Global Next Generation Cancer Diagnostic Devices Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Type
5.3.1. Next Generation Sequencing
5.3.2. qPCR & Multiplexing
5.3.3. Lab-on- a- chip (LOAC)
5.3.4. Protein Microarrays
5.3.5. DNA Microarrays
5.3.6. Reverse Transcriptase-PCR (RT-PCR)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Next Generation Cancer Diagnostic Devices Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Application
6.3.1. Biomarker Development
6.3.2. CTC Analysis
6.3.3. Proteomic Analysis
6.3.4. Epigenetic Analysis
6.3.5. Genetic Analysis
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Next Generation Cancer Diagnostic Devices Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Next Generation Cancer Diagnostic Devices Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Next Generation Cancer Diagnostic Devices Demand Share Forecast, 2019-2026
9. North America Next Generation Cancer Diagnostic Devices Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Application
9.4.1. Biomarker Development
9.4.2. CTC Analysis
9.4.3. Proteomic Analysis
9.4.4. Epigenetic Analysis
9.4.5. Genetic Analysis
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Type
9.7.1. Next Generation Sequencing
9.7.2. qPCR & Multiplexing
9.7.3. Lab-on- a- chip (LOAC)
9.7.4. Protein Microarrays
9.7.5. DNA Microarrays
9.7.6. Reverse Transcriptase-PCR (RT-PCR)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Next Generation Cancer Diagnostic Devices Demand Share Forecast, 2019-2026
10. Latin America Next Generation Cancer Diagnostic Devices Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Application
10.4.1. Biomarker Development
10.4.2. CTC Analysis
10.4.3. Proteomic Analysis
10.4.4. Epigenetic Analysis
10.4.5. Genetic Analysis
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Type
10.7.1. Next Generation Sequencing
10.7.2. qPCR & Multiplexing
10.7.3. Lab-on- a- chip (LOAC)
10.7.4. Protein Microarrays
10.7.5. DNA Microarrays
10.7.6. Reverse Transcriptase-PCR (RT-PCR)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Next Generation Cancer Diagnostic Devices Demand Share Forecast, 2019-2026
11. Europe Next Generation Cancer Diagnostic Devices Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Application
11.4.1. Biomarker Development
11.4.2. CTC Analysis
11.4.3. Proteomic Analysis
11.4.4. Epigenetic Analysis
11.4.5. Genetic Analysis
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Type
11.7.1. Net Generation Sequencing
11.7.2. qPCR & Multiplexing
11.7.3. Lab-on- a- chip (LOAC)
11.7.4. Protein Microarrays
11.7.5. DNA Microarrays
11.7.6. Reverse Transcriptase-PCR (RT-PCR)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Next Generation Cancer Diagnostic Devices Demand Share, 2019-2026
12. Asia Pacific Next Generation Cancer Diagnostic Devices Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Application
12.4.1. Biomarker Development
12.4.2. CTC Analysis
12.4.3. Proteomic Analysis
12.4.4. Epigenetic Analysis
12.4.5. Genetic Analysis
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Type
12.7.1. Next Generation Sequencing
12.7.2. qPCR & Multiplexing
12.7.3. Lab-on- a- chip (LOAC)
12.7.4. Protein Microarrays
12.7.5. DNA Microarrays
12.7.6. Reverse Transcriptase-PCR (RT-PCR)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Next Generation Cancer Diagnostic Devices Demand Share, 2019-2026
13. Middle East & Africa Next Generation Cancer Diagnostic Devices Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Application
13.4.1. Biomarker Development
13.4.2. CTC Analysis
13.4.3. Proteomic Analysis
13.4.4. Epigenetic Analysis
13.4.5. Genetic Analysis
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Next Generation Cancer Diagnostic Devices Market Size and Volume Forecast by Type
13.7.1. Next Generation Sequencing
13.7.2. qPCR & Multiplexing
13.7.3. Lab-on- a- chip (LOAC)
13.7.4. Protein Microarrays
13.7.5. DNA Microarrays
13.7.6. Reverse Transcriptase-PCR (RT-PCR)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Next Generation Cancer Diagnostic Devices Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Next Generation Cancer Diagnostic Devices Market: Market Share Analysis
14.2. Next Generation Cancer Diagnostic Devices Distributors and Customers
14.3. Next Generation Cancer Diagnostic Devices Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche Holding Ltd.(Switzerland)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Abbott Laboratories(US)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Siemens Healthcare(Germany)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Agilent Technologies Inc(Germany)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Illumina Inc.(US)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Becton Dickinson and Co.(US)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. QIAGEN N.V.(Germany)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Affymetrix Inc.(US)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Johnson & Johnson(US)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Thermo Fisher Scientific Inc.(US)
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. GE Healthcare(England)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Life Technologies Corp.(US)
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Luminex Corp.(US)
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Cepheid Inc.(US)
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Allegro Diagnostics Corp.(Brazil)
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
&nbs
